Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
27.17 USD
-1.13%
Market Closed
Updated:
May 22, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
22.2
Current
22.8
Median
13.7
Industry
Lower
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=22.2
Enterprise Value
/
20.8B
EBITDA
939.3m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| US |
|
Royalty Pharma PLC
NASDAQ:RPRX
|
16.2B USD | 22.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
763.3B USD | 60.8 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 34.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364B USD | 11.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
331.2B USD | 35.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
190.9B GBP | 174.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
185.5B CHF | 9.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.6B CHF | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.8B USD | 12.7 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
8.2
2-Years Forward
EV/EBITDA
7.4
3-Years Forward
EV/EBITDA
6.8
You don't have any saved screeners yet
